Keros Therapeutics (KROS) Operating Expenses (2019 - 2026)

Keros Therapeutics (KROS) has reported Operating Expenses for 8 consecutive years, with $30.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 46.65% year-over-year to $30.9 million; the trailing twelve-month figure through Jun 2026 stood at $148.2 million (down 36.26% YoY), and the FY2025 full-year result was $176.5 million, down 17.67% from the prior year.
• Operating Expenses improved to $30.9 million in Q2 2026 per KROS's latest filing, from $29.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $59.2 million in Q1 2025 and bottomed at $24.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $41.6 million across 5 years, with a median of $41.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 96.46% in 2022, then tumbled 49.79% in 2025.
• Over 5 years, Operating Expenses stood at $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then gained by 20.81% to $56.3 million in 2024, then slumped by 47.32% to $29.7 million in 2025, then rose by 4.32% to $30.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $30.9 million, $29.7 million, and $29.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.